Authors

  • Aslonov I.F.

Keywords:

Tuberculosis (TB), Drug-resistant tuberculosis (MDR-TB), Nephrotoxicity, Kidney function, Glomerular filtration rate (GFR / CKD-EPI), Cystatin C.

References

Abdusalomova, M.;Denisiuk, O.; Davtyan, H.; Gadoev, J.;Abdusamatova, B.; Parpieva, N.;Sodikov, A. Adverse Drug Reactionsamong Children with Tuberculosis inTashkent, Uzbekistan, 2019. Int. J.Environ. Res. Public Health 2021,18,7574. https://doi.org/10.3390/ ijerph18147574

Adingwupu, Ogechi M., et al. "Cystatin C as a GFR estimation marker in acute and chronic illness: a systematic review." Kidney Medicine 5.12 (2023): 100727.

Al-Bari MAA, Peake N, Eid N. Tuberculosis-diabetes comorbidities: Mechanistic insights for clinical considerations and treatment challenges. World J Diabetes. 2024 May 15;15(5):853-866. doi: 10.4239/wjd. v15.i5.853. PMID: 38766427; PMCID: PMC11099355.

Chang CH, Chang LY, Ko JC, Wen YF, Chang CJ, Keng LT, Tsou PH, Yu KL, Wang JY, Yu CJ. Incidence of and Risk Factors for Acute Kidney Injury During Antituberculosis Treatment: A Prospective Cohort Study and Literature Review. Infect Dis Ther. 2023 Mar;12(3):919-931. doi: 10.1007/s40121-023-00761-w. Epub 2023 Feb 11. PMID: 36773200; PMCID: PMC10017892.

Du ZX, Chang FQ, Wang ZJ, Zhou DM, Li Y, Yang JH. A risk prediction model for acute kidney injury in patients with pulmonary tuberculosis during anti-tuberculosis treatment. Ren Fail. 2022 Dec;44(1):625-635. doi: 10.1080/0886022X.2022.2058405. PMID: 35373713; PMCID: PMC8986302.

Gautam, S., Shrestha, N., Mahato, S. et al. Diabetes among tuberculosis patients and its impact on tuberculosis treatment in South Asia: a systematic review and meta-analysis. Sci Rep 11, 2113 (2021). https://doi.org/10.1038/s41598-021-81057-2

Kansiime G, Aklilu AM, Baluku JB, Yasmin F, Kanyesigye M, Muzoora CK, Wilson FP, Bajunirwe F, Brewster U, Kalyesubula R. Incidence of Acute Kidney Injury and Associated Mortality among Individuals with Drug-Susceptible Tuberculosis in Uganda. Kidney360. 2024 Oct 1;5(10):1446-1454. doi: 10.34067/KID.0000000000000551. Epub 2024 Aug 14. PMID: 39141693; PMCID: PMC11556924.

Ostermann M, Zarbock A, Goldstein S, et al. Recommendations on Acute Kidney Injury Biomarkers From the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement. JAMA Netw Open. 2020;3(10): e2019209. doi:10.1001/jamanetworkopen.2020. 19209

Patel ML, Shyam R, Bharti H, Sachan R, Gupta KK, Parihar A. Evaluation of Serum Cystatin C as an Early Biomarker of Acute Kidney Injury in Patients with Acute Pancreatitis. Indian J Crit Care Med. 2020 Sep;24(9):777-782. doi: 10.5005/jp-journals-10071-23572. PMID: 33132559; PMCID: PMC7584843.

Peng P, Fu XC, Wang Y, Zheng X, Bian L, Zhati N, et al. (2024) The value of serum cystatin c in predicting acute kidney injury after cardiac surgery: A systematic review and meta-analysis. PLoS ONE 19(11): e0310049. https://doi.org/10.1371/journal.pone.0310049

Raznatovska, O.M. and Khudiakov, H.V. 2019. Diagnostic value of cystatin C in patients with drug-resistant pulmonary tuberculosis receiving palliative care. Zaporozhye Medical Journal. 21, 2 (Apr. 2019). DOI: https://doi.org/10.14739/2310-1210.2019.2.161488.

Sokova EA, Arkhipov VV, Mazerkina IA, Muslimova OV. Some aspects of assessing drug-induced kidney injury. Safety and risk of pharmacotherapy. 2020;8(3):123–133. https://doi.org/10.30895/2312-7821-2020-8-3-123-133